IL-18 revives dysfunctional CAR-T cells
Yan-Ruide Li, Yichen Zhu, Lili Yang
Abstract
IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.
Topics & Concepts
Dysfunctional familyMedicineClinical psychologyCAR-T cell therapy researchImmune Cell Function and InteractionT-cell and B-cell Immunology